BMJ Global Health

Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin ...

Introduction Prior to 2020, treatment options for multidrug-resistant tuberculosis (MDR-TB) were limited and typically ...

TaskUs, Inc. (NASDAQ:TASK) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call Transcript November 7, 2025 TaskUs, Inc. misses on earnings expectations. Reported EPS is $0.337 EPS, ...